Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
January 2021
-
Media ReleaseNovartis and GSK announce collaboration to support scientific research into genetic diversity in AfricaProject Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
-
Media ReleaseNovartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently…
-
Media ReleaseNovartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGeneAgreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and…
December 2020
-
Key ReleaseNovartis receives complete response letter from U.S. FDA for inclisiranThe U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related…
-
Media ReleaseNovartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisitionThe agreement includes two clinical stage molecules for schizophrenia and movement disorders and MIJ821, a clinical stage molecule previously licensed exclusively by Novartis for addressing treatment…
-
Media ReleaseNovartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3GParoxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life1–3C3 glomerulopathy (C3G) is a…
-
Media ReleaseNovartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEFThe Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval…
-
Media ReleaseNovartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edemaIn Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1In a…
-
Media ReleaseNovartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1 Detailed…
-
Media ReleaseNovartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3 Cardiovascular disease causes 3.9…
-
Media ReleaseNovartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancerFindings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1Benefit seen…
-
Media ReleaseNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancerMONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7…
Pagination
- ‹ Previous page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- …
- 100
- › Next page